Capmatinib

Drug Profile

Capmatinib

Alternative Names: INC-280; INCB-028060; INCB-28060

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Developer Array BioPharma; Novartis Oncology
  • Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Imidazoles; Quinolines; Small molecules; Triazines
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma; Hepatocellular carcinoma; Malignant melanoma; Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Head and neck cancer
  • Phase I Renal cell carcinoma; Solid tumours

Most Recent Events

  • 10 Nov 2016 Novartis terminates a phase II trial in Malignant melanoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Switzerland, Spain, Germany, Canada, Australia, USA due to scientific and business considerations (PO) (NCT01820364)
  • 07 Oct 2016 Novartis Pharmaceuticals plans a phase I trial for solid tumour (Late-stage disease; Second-line therapy or greater) in Austria, Germany, Greece, Spain, Netherlands, Sweden, USA and United Kingdom (NCT02925104)
  • 30 Aug 2016 Novartis withdraws a phase II trial in Hepatocellular carcinoma (Second-line therapy or greater) prior to enrolment in Australia, Spain and USA (NCT01964235)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top